K-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

ycwoo
2022-12-22

ORIC Pharmaceuticals Surges 44% on Pfizer Collaboration, Investment

ORIC Pharmaceuticals (NASDAQ:ORIC) soared 44% in premarket trading Thursday after announcing both a

ORIC Pharmaceuticals Surges 44% on Pfizer Collaboration, Investment

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9922162576,"tweetId":"9922162576","gmtCreate":1671720049396,"gmtModify":1676538581836,"author":{"id":3565146699964497,"authorId":3565146699964497,"authorIdStr":"3565146699964497","name":"ycwoo","avatar":"https://community-static.tradeup.com/news/2f48b4bbc66c0bf509f7199142c1a2f2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>K</p></body></html>","htmlText":"<html><head></head><body><p>K</p></body></html>","text":"K","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9922162576","repostId":1100927875,"repostType":4,"repost":{"id":"1100927875","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1671700998,"share":"https://www.laohu8.com/m/news/1100927875?lang=&edition=full","pubTime":"2022-12-22 17:23","market":"us","language":"en","title":"ORIC Pharmaceuticals Surges 44% on Pfizer Collaboration, Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1100927875","media":"Tiger Newspress","summary":"ORIC Pharmaceuticals (NASDAQ:ORIC) soared 44% in premarket trading Thursday after announcing both a ","content":"<html><head></head><body><p>ORIC Pharmaceuticals (NASDAQ:ORIC) soared 44% in premarket trading Thursday after announcing both a collaboration on a multiple myeloma candidate with Pfizer (NYSE:PFE) as well as an equity investment from the drug giant.</p><p><img src=\"https://static.tigerbbs.com/d1a5dcb20234c155353b0de87ceda427\" tg-width=\"866\" tg-height=\"619\" width=\"100%\" height=\"auto\"/></p><p>ORIC-533, a CD73 inhibitor, is currently in phase 1. The companies said the candidate could be moved into phase 2 in a combination study with Pfizer&#39;s (PFE) elranatamab, a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody under investigation for multiple myeloma.</p><p>ORIC (ORIC) said the $25M investment from Pfizer (PFE) means its cash runway is extended into H1 2025.</p><p>Seeking Alpha&#39;s Quant Rating views ORIC (ORIC) as a hold.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORIC Pharmaceuticals Surges 44% on Pfizer Collaboration, Investment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORIC Pharmaceuticals Surges 44% on Pfizer Collaboration, Investment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-12-22 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>ORIC Pharmaceuticals (NASDAQ:ORIC) soared 44% in premarket trading Thursday after announcing both a collaboration on a multiple myeloma candidate with Pfizer (NYSE:PFE) as well as an equity investment from the drug giant.</p><p><img src=\"https://static.tigerbbs.com/d1a5dcb20234c155353b0de87ceda427\" tg-width=\"866\" tg-height=\"619\" width=\"100%\" height=\"auto\"/></p><p>ORIC-533, a CD73 inhibitor, is currently in phase 1. The companies said the candidate could be moved into phase 2 in a combination study with Pfizer&#39;s (PFE) elranatamab, a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody under investigation for multiple myeloma.</p><p>ORIC (ORIC) said the $25M investment from Pfizer (PFE) means its cash runway is extended into H1 2025.</p><p>Seeking Alpha&#39;s Quant Rating views ORIC (ORIC) as a hold.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORIC":"Oric Pharmaceuticals Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100927875","content_text":"ORIC Pharmaceuticals (NASDAQ:ORIC) soared 44% in premarket trading Thursday after announcing both a collaboration on a multiple myeloma candidate with Pfizer (NYSE:PFE) as well as an equity investment from the drug giant.ORIC-533, a CD73 inhibitor, is currently in phase 1. The companies said the candidate could be moved into phase 2 in a combination study with Pfizer's (PFE) elranatamab, a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody under investigation for multiple myeloma.ORIC (ORIC) said the $25M investment from Pfizer (PFE) means its cash runway is extended into H1 2025.Seeking Alpha's Quant Rating views ORIC (ORIC) as a hold.","news_type":1},"isVote":1,"tweetType":1,"viewCount":124,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}